Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has been given a consensus rating of “Moderate Buy” by the nineteen research firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, six have given a hold recommendation, eleven have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $37.56.

Several research firms have weighed in on NTLA. StockNews.com upgraded shares of Intellia Therapeutics to a “sell” rating in a research note on Monday, March 3rd. Wedbush reiterated a “neutral” rating and issued a $10.00 price objective (down from $14.00) on shares of Intellia Therapeutics in a report on Friday, January 10th. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $13.00 price target (down previously from $45.00) on shares of Intellia Therapeutics in a research note on Friday, February 28th. Barclays cut their price objective on Intellia Therapeutics from $55.00 to $26.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. Finally, BMO Capital Markets lowered their price target on Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating on the stock in a report on Friday, January 10th.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. GF Fund Management CO. LTD. acquired a new position in shares of Intellia Therapeutics in the 4th quarter valued at $25,000. Sterling Capital Management LLC raised its position in Intellia Therapeutics by 866.2% in the fourth quarter. Sterling Capital Management LLC now owns 3,198 shares of the company’s stock worth $37,000 after purchasing an additional 2,867 shares in the last quarter. Whipplewood Advisors LLC bought a new position in Intellia Therapeutics during the fourth quarter worth about $40,000. Resona Asset Management Co. Ltd. acquired a new stake in Intellia Therapeutics during the fourth quarter valued at approximately $43,000. Finally, Jones Financial Companies Lllp grew its stake in shares of Intellia Therapeutics by 140.9% in the 4th quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company’s stock valued at $45,000 after purchasing an additional 2,280 shares during the period. 88.77% of the stock is currently owned by institutional investors and hedge funds.

Intellia Therapeutics Trading Up 1.2 %

Shares of NTLA stock opened at $7.50 on Tuesday. The stock’s fifty day simple moving average is $9.09 and its 200-day simple moving average is $12.44. The company has a market capitalization of $776.38 million, a price-to-earnings ratio of -1.38 and a beta of 2.23. Intellia Therapeutics has a 1-year low of $5.90 and a 1-year high of $28.18.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.